Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Cancer of breast

Breast cancer is the second most commonly diagnosed cancer worldwide, behind only lung cancers; this is even more remarkable when its relative rarity in males is noted (males

...


Read more on Cancer of breast

 

 

Latest news articles

Added 2 days ago Drug news

FDA approves Nerlynx (neratinib) to treat patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy.- Puma Biotechnology

Puma Biotechnology announced that the FDA has approved Nerlynx (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor...

Added 5 days ago Drug news

Mylan N.V. and Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies' proposed biosimilar trastuzumab.

Mylan N.V. and Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies' proposed...

Added 13 days ago Drug news

Celgene and BeiGene Ltd collaborate to licence BGB A317 an advanced PD I inhibitor to Celgene and to licence certain Celgene products to BeiGene in China.

Celgene Corporation and BeiGene, Ltd. entered into a strategic collaboration to develop and commercialize BeiGene's investigational anti-programmed cell death protein...

Search all news articles for Cancer of breast
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone


Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

Visit Fluid Management


Guidelines

Breast screening: clinical guidelines for screening assessment

The aim of assessment is to obtain a definitive and timely diagnosis of all potential abnormalities detected during screening.

Added 2 months ago

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The updated ESMO Clinical Practice Guidelines provide information on the current management of primary breast cancer, including screening, diagnosis and...

Added 2 years ago

Preventing excess weight gain

This guideline makes recommendations on behaviours that may help people maintain a healthy weight or prevent excess weight gain. The...

Added 2 years ago

Search all guidelines for Cancer of breast
 

Journal articles

Recent advances of highly selective CDK4/6 inhibitors in breast cancer.

Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which are pivotal ...

Added 1 month ago

Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.

The cyclin-dependent kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents

Added 1 month ago

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.

Oral palbociclib (Ibrance®) is a first-in-class, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (i.e. a CDK4/6 inhibitor). It is indicated for the treatment of women with HR-positive, HER2-negative ...

Added 1 month ago

Search all journal articles for Cancer of breast
 

Clinical trials

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)

This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in participants with metastatic...

Added 3 months ago

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with...

Added 3 months ago

Search all clinical trials for Cancer of breast
 

Blog Posts

Fiona Holland

What to say and do when someone has cancer

Posted 5 months ago

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

Hugh Harvey

Metrics Madness

Posted 1 year ago

You shouldn't judge a book by its cover. That much is true, but it's also common sense not to judge a book by measuring the whiteness of its pages, or the amount of hamsters you can place on it. So why do we measure the fabulous NHS with nonsense metrics?

CME

Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Cancer of breast